OSUR OraSure Technologies Inc.

OraSure to Present at the J.P Morgan Healthcare Conference

OraSure to Present at the J.P Morgan Healthcare Conference

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT.

A live webcast and replay of the presentation will be available in the “Events and Presentations” section of OraSure’s investor relations website at .

About OraSure Technologies, Inc. 

OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit

Investor Contact:Media Contact:
Jason PlagmanAmy Koch
VP, Investor RelationsDirector, Corporate Communications


EN
07/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OraSure Technologies Inc.

 PRESS RELEASE

OraSure to Present at the J.P Morgan Healthcare Conference

OraSure to Present at the J.P Morgan Healthcare Conference BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. OraSure’s presentation is scheduled for Thursday, January 16, 2025 at 9:00 a.m. PT. A live webcast and replay of the presentation will be available in the “Events and Presentations” section of OraSure’s investor relations website at ....

 PRESS RELEASE

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescen...

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Tuesday, January 7th by OraSure Technologies, Inc. (NASDAQ: OSUR), please note that the first sentence of the release (read "OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents.") is incomplete. The corrected release follows:  OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that The...

 PRESS RELEASE

OraQuick® HIV Self-Test Now Approved for Use in Adolescents

OraQuick® HIV Self-Test Now Approved for Use in Adolescents BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older. According to the most recent data available from the Centers for Disease Control & Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young people aged 13 to 24, and ...

 PRESS RELEASE

OraSure Technologies Acquires Sherlock Biosciences

OraSure Technologies Acquires Sherlock Biosciences BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specif...

 PRESS RELEASE

OraSure Receives Federal Funding for Development of Marburg Virus Rapi...

OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and R...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch